After rising 25% in one month, the US biotech sector plunged on Friday.

```

The US biotech sector suffered a large-scale sell-off on Friday, as previously accumulated substantial gains triggered concentrated profit-taking, with the sector ETF representing a single-day decline of 4%.

Moderna's stock price fell 11% to $68.50, ImmunityBio dropped 8% to $8.16, and Sarepta Therapeutics fell 8% to $18.84. None of these three companies had any negative news to trigger this decline. The market generally interprets this pullback as profit-taking at high levels. Meanwhile, there were clear signs of sector rotation—funds shifted from high-beta biotech stocks to defensive large-cap pharmaceutical companies.

The background for the sector's overall pressure is clear. The SPDR S&P Biotech ETF (XBI), which represents the biotech sector, fell 4% on Friday, while Eli Lilly only dropped 3%, and Johnson & Johnson fell just 1%. Large pharmaceutical companies held up relatively well, indicating that market capital is undergoing structural reallocation rather than a complete exit from the healthcare sector.

Profit-Taking Dominates This Round of Declines

This decline occurred after the three companies had risen sharply earlier this year. As of Thursday's close, Moderna had accumulated a 160% gain in the year, and ImmunityBio's gain reached as high as 348%. Against this backdrop, none of the individual stocks saw any fundamental negative news.

From a recent fundamental perspective, the latest developments of these companies are actually positive. ImmunityBio saw Q1 revenue reach $44.21 million, up 168% year-on-year, with ANKTIVA sales also increasing 168% over the same period. Sarepta Therapeutics was just upgraded by Wolfe Research to "Outperform," with a target price of $27, implying a 34% upside from Thursday's closing price. Moderna's Q1 revenue was $389 million, exceeding consensus estimates by 65%, with management reiterating a full-year revenue increase of up to 10%.

With no negative catalysts and relatively strong fundamentals, the logic of this decline points to one reason—a concentrated round of profit-taking after parabolic gains.

Large Pharmaceutical Companies Are Relatively Resistant to Declines, Clear Signals of Rotation

The sector split on Friday provided important clues about capital flows in the market. Eli Lilly's year-to-date gain is still 10%, Johnson & Johnson's gain is 24%, and both suffered much smaller declines compared to high-beta biotech stocks.

This price gap reveals a clear rotation logic: funds are flowing out of unprofitable, highly volatile small-cap biotech stocks and staying in defensive, stable-profit large pharmaceutical companies. This is not a systemic reduction in healthcare sector holdings, but rather an active adjustment of risk appetite.

XBI uses an equal-weight structure, with Moderna, ImmunityBio, and Sarepta all constituent stocks. Friday's overall decline shows this adjustment was not caused by a single stock, but rather a broad sector pullback.

It is worth noting that even with Friday's sharp drop, XBI's cumulative 12-month gain remains as high as 78%. This data suggests that this adjustment is more of a normal fluctuation after rapid gains, rather than the start of a trend reversal. However, XBI's equal-weight nature also means that if multiple stocks decline simultaneously within the sector, the ETF's drop will often be amplified.

Divergence Intensifies for Moderna

Among today's three sharply declining stocks, the bull/bear debate over Moderna is the most representative.

Bullish logic centers on pipeline progress: the FDA decision date (PDUFA) for its flu vaccine mRNA-1010 is set for August 5th, plus multiple branded products such as Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX, as well as a year-end cash target of $4.5–5 billion set by management, providing ample operating space for the company.

Bearish arguments focus on valuation and financial pressure: Moderna's stock is still down 71% from five years ago, Q1 GAAP net loss reached $1.34 billion, cash consumption remains high, and the consensus analyst target price is noticeably below the current stock price. Friday's over-10% single-day drop vividly highlights the stock's high-beta character and the resulting double-sided risk.

Focus for the Market Ahead

In the short term, the market focus is whether XBI can stabilize before the close; if the decline accelerates, it means the sector rotation still has room to develop further. For Moderna, the FDA's flu vaccine approval result on August 5th is the next important catalyst with a clear time node.

In summary, this sharp drop in the biotech sector is closer to a technical correction after historic gains, rather than a substantial fundamental deterioration. For investors holding these stocks, striking a balance between high-beta exposure and potential catalysts may be the key issue worth considering at this stage.

Risk Warning and DisclaimerThe market is risky, and investment should be approached with caution. This article does not constitute individual investment advice, nor does it consider the specific investment objectives, financial situation, or needs of any particular user. Users should consider whether any opinions, views, or conclusions in this article are suitable for their particular situation. Investments are made at your own risk. ```